Fulcrum Therapeutics, Inc.
No enriched coverage for $FULC in the last 7 days.
No SEC Form 4 filings for $FULC in the last 30 days.
See all $FULC insider activity →Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.
Slate Medicines dosed the first participant in its Phase 1 trial for SLTE-1009, a therapy for advanced solid tumors. The company plans to merge with Fulcrum Therapeutics (FULC), trading as SLTE post-merger. Topline data is expected mid-2027. FULC stock closed at $3.86, up 0.52% in pre-market trading.
Fulcrum Therapeutics (FULC) is merging with Slate Medicines, a migraine-focused biotech, in an all-stock deal. Legacy Fulcrum shareholders will own 5% of the combined company, while Slate and PIPE investors will own 95%. Fulcrum plans to distribute a $270M cash dividend, approximately $3.54 per share, before the merger. The transaction is expected to close in Q4 2026, subject to approvals. Slate's lead asset, SLTE-1009, is in early-stage development with no publicly disclosed human efficacy data
Recent FULC coverage spans mergers & acquisitions, corporate actions and market movers.
Stock fell sharply as lead asset loss raises doubts on growth.
Positive trial initiation may boost confidence in the upcoming merger and future pipeline, supporting near‑term upside for Fulcrum.
The merger will convert Fulcrum into a cash‑distribution vehicle with a small residual stake in the combined migraine biotech, creating immediate shareholder value and future upside tied to Slate's pipeline.
Merger creates a larger migraine‑focused company; dilution and ownership shift noted.
Deal announcement and financing commitments can re-rate merger probability and near-term capital structure expectations for Fulcrum.
alphai scores every news story that mentions FULC with an AI model for sentiment and relevance, and aggregates insider trades from Fulcrum Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.
2 min readSlate Medicines dosed the first participant in its Phase 1 trial for SLTE-1009, a therapy for advanced solid tumors. The company plans to merge with Fulcrum Therapeutics (FULC), trading as SLTE post-merger. Topline data is expected mid-2027. FULC stock closed at $3.86, up 0.52% in pre-market trading.
2 min readFulcrum Therapeutics (FULC) is merging with Slate Medicines, a migraine-focused biotech, in an all-stock deal. Legacy Fulcrum shareholders will own 5% of the combined company, while Slate and PIPE investors will own 95%. Fulcrum plans to distribute a $270M cash dividend, approximately $3.54 per share, before the merger. The transaction is expected to close in Q4 2026, subject to approvals. Slate's lead asset, SLTE-1009, is in early-stage development with no publicly disclosed human efficacy data
3 min readUltragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readFulcrum Therapeutics (Nasdaq: FULC) and Slate Medicines announced a definitive all-stock merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq as SLTE. Slate secured commitments for an oversubscribed concurrent private placement of $245 million led by Frazier Life Sciences, with other healthcare investors participating.
2 min readFulcrum Therapeutics (FULC) and Slate Medicines (SLTE) announced a definitive all-stock merger to form a Nasdaq-listed company under Slate’s name and ticker. The combined firm plans to advance Slate’s SLTE-1009, a PACAP/VIP monoclonal antibody for migraine prevention, into Phase 1 in Australia. Slate secured $245M financing. Fulcrum shareholders expected 5% ownership; deal to close Q4 2026.
4 min readFulcrum Therapeutics, Inc. (FULC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies Combined company to operate as Slate Medicines and focus on advancing Slate’s portfolio of next-generation migraine therapeutics Slate’s lead product cand
4 min readFulcrum Therapeutics shares rose about 4.8% pre-open after the company agreed to merge with clinical-stage Slate Medicines in an all-stock deal. The combined company will focus on Slate’s SLTE-1009 migraine antibody. Fulcrum is expected to add about $20.3M net cash and pay an estimated $270M dividend before closing, with a $245M oversubscribed private placement. Nasdaq trading under SLTE is expected after a Q4 2026 close.
4 min readFulcrum Therapeutics, Inc. (FULC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance an
2 min readTANG KEVIN purchased 167,616 indirectly-held shares of Fulcrum Therapeutics, Inc. (FULC) at an average of $3.55 ($3.52–$3.56, $0.59M total) across 2 trades over 2026-07-16 to 2026-07-17.
2 min read
